iLoF: Accelerating access to personalized medicine, from a drop of blood

The iLoF founding team (L to R): CTO Joana Paiva, CEO Luís Valente, CSO Paula Sampaio and COO Mehak Mumtaz ©iLoF

Backed by Microsoft’s venture fund M12, Mayfield and Melinda Gates’s Pivotal Ventures, iLoF focuses on painless screening to facilitate disease detection, forecasting and drug development, from Alzheimer’s to Covid-19

Imagine getting your own personalized medical treatment for an illness – say, diabetes or cancer – created using all the biological, medical, behavioral and environmental information known about you. iLoF, a Porto- and Oxford-based precision medicine startup, is working to make that possible, from needing just a single drop of blood from the patient.The goal: better predictions and preventative measures in early diagnostics, as well as accelerating and optimizing drug and treatment development – through inexpensive and non-invasive patient screening and stratification."iLoF was born...
Limited Reading

The rest of the content is only available if you are logged in.

Limited Reading

Edited by Bernice Tang

Your payment was not successful.

Please make sure you have entered your payment details correctly. Or try again in a few moments.

small logo

The discount code you entered is invalid

Please make sure you have entered your discount code correctly. Or try again in a few moments.

Download successful.

Your sample has been sent. Please check your email.

By accessing and using and all pages within the domain (the “Website”), You accept and agree to have read, understood, accepted and agreed to be bound by the Terms of Use and Privacy Policy in full. If you disagree with all or any part of these Terms of Use and Privacy Policy, please do not use or continue any further use of this website. You acknowledge that you are aware that this Website contains an archive of existing content as at 31 December 2021 and is not being actively managed. We are under no obligation to update the content on this Website and, accordingly, no new content or articles will be posted to the Website after 31 December 2021.